The National Medical Products Administration (NMPA) of China has issued revisions to its clinical trial policies in an effort to shorten drug development timelines and encourage innovation. The revised guidelines, which became effective on September 2, 2025, are expected to reduce approval timelines by 30% and to reduce the regulatory burden for drug companies.
The most significant change was the adoption of adaptive trial designs, which allows real-time modifications to the trial protocol based on data from the trial while introducing tougher ethical standards for patient safety and informed consent. Public registration of trials and early release of trial results will now be required to improve transparency.
As the NMPA works to better align with international standards, it hopes to increase foreign investment and restore China as a top destination for clinical research. Improved collaboration with regulators in the US and Europe may ultimately facilitate mutual recognition of trial data to enable global drug development. The reforms are believed to promote innovation for biologics and personalized medicine and support the development of next-generation therapeutics in China.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.